Trials Sponsors Conditions Drugs Pricing

Conditions

Lung Cancers Neuroendocrine Tumors Pancreatic Cancer Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

SUVmax of lesion uptake value
60 minutes after administration

Interventions

PET-CT examinationOther

Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Participants were recruited through hospital electronic records and community health centers

You may qualify if:

\- 1. Volunteer for the trial, with the patient or their legal guardian signing the informed consent form; 2. Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends; 3. Other imaging examination methods (CT, MRI, etc.) revealed tumor occupying lesions; 4. Patients with lung cancer, thyroid cancer, pancreatic cancer, melanoma, and neuroendocrine tumors who can obtain the final pathological results.

Sponsors & Collaborators

Nanjing First Hospital, Nanjing Medical University
Otherlead

Study Sites (1)

Nanjing First Hospital

Nanjing, Jiangsu, 210001, China

RECRUITING

Feng Wang, M.D.CONTACT+8602552271491 fengwangcn@hotmail.com

MeSH Terms

Conditions

Lung NeoplasmsPancreatic NeoplasmsNeuroendocrine TumorsThyroid Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesDigestive System NeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Central Study Contacts

Feng Wang

CONTACT

+8602552271491 fengwangcn@hotmail.com

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Chief physician

Study Record Dates

First Submitted

April 18, 2025

First Posted

April 22, 2025

Study Start

April 10, 2025

Actual (reported)

Primary Completion

January 31, 2026

Estimated (date passed)

18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations